Cargando…
Clinical Management of HIV Drug Resistance
Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. M...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185705/ https://www.ncbi.nlm.nih.gov/pubmed/21994737 http://dx.doi.org/10.3390/v3040347 |
_version_ | 1782213251555131392 |
---|---|
author | Cortez, Karoll J. Maldarelli, Frank |
author_facet | Cortez, Karoll J. Maldarelli, Frank |
author_sort | Cortez, Karoll J. |
collection | PubMed |
description | Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy. |
format | Online Article Text |
id | pubmed-3185705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-31857052011-10-12 Clinical Management of HIV Drug Resistance Cortez, Karoll J. Maldarelli, Frank Viruses Review Combination antiretroviral therapy for HIV-1 infection has resulted in profound reductions in viremia and is associated with marked improvements in morbidity and mortality. Therapy is not curative, however, and prolonged therapy is complicated by drug toxicity and the emergence of drug resistance. Management of clinical drug resistance requires in depth evaluation, and includes extensive history, physical examination and laboratory studies. Appropriate use of resistance testing provides valuable information useful in constructing regimens for treatment-experienced individuals with viremia during therapy. This review outlines the emergence of drug resistance in vivo, and describes clinical evaluation and therapeutic options of the individual with rebound viremia during therapy. Molecular Diversity Preservation International (MDPI) 2011-04-14 /pmc/articles/PMC3185705/ /pubmed/21994737 http://dx.doi.org/10.3390/v3040347 Text en © 2011 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Cortez, Karoll J. Maldarelli, Frank Clinical Management of HIV Drug Resistance |
title | Clinical Management of HIV Drug Resistance |
title_full | Clinical Management of HIV Drug Resistance |
title_fullStr | Clinical Management of HIV Drug Resistance |
title_full_unstemmed | Clinical Management of HIV Drug Resistance |
title_short | Clinical Management of HIV Drug Resistance |
title_sort | clinical management of hiv drug resistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185705/ https://www.ncbi.nlm.nih.gov/pubmed/21994737 http://dx.doi.org/10.3390/v3040347 |
work_keys_str_mv | AT cortezkarollj clinicalmanagementofhivdrugresistance AT maldarellifrank clinicalmanagementofhivdrugresistance |